Alexander Mayweg

Currently, Alexander Mayweg is Chairman-Management Board at Matterhorn Biosciences AG, Chairman at T-Knife GmbH, Cimeio Therapeutics AG, and Vertical Bio AG, Director at Enterprise Therapeutics Ltd. since 2018, Monte Rosa Therapeutics AG, and Bright Peak Therapeutics AG, Managing Director at Versant Ventures (Switzerland) GmbH since 2020, Director at Bright Peak Therapeutics, Inc. since 2017, President, Treasurer & Director at Revelio Therapeutics, Inc., and Chief Scientific Officer at Ridgeline Therapeutics and Ridgeline Discovery GmbH since 2017.
Formerly, Dr. Mayweg was Director at Monte Rosa Therapeutics, Inc. from 2018 to 2024, Director at Black Diamond Therapeutics, Inc. from 2017 to 2024, and Vice President & Global Head-Medicinal Chemistry at Roche Holding AG and F.
Hoffmann-La Roche Ltd. from 2013 to 2016.
Education includes a doctorate from the University of Oxford conferred in 2001 and an undergraduate degree from Imperial College London conferred in 1998.